|
1
|
Marioni G, Marchese-Ragona R, Cartei G,
Marchese F and Staffieri A: Current opinion in diagnosis and
treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Almadori G, Bussu F, Cadoni G, Galli J,
Paludetti G and Maurizi M: Molecular markers in laryngeal squamous
cell carcinoma: Towards an integrated clinicobiological approach.
Eur J Cancer. 41:683–693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hashibe M, Brennan P, Benhamou S,
Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova
E, Fernandez L, et al: Alcohol drinking in never users of tobacco,
cigarette smoking in never drinkers and the risk of head and neck
cancer: Pooled analysis in the International Head and Neck Cancer
Epidemiology Consortium. J Natl Cancer Inst. 99:777–789. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brandstorp-Boesen J, Falk RS, Boysen M and
Brøndbo K: Long-term trends in gender, T-stage, subsite and
treatment for laryngeal cancer at a single center. Eur Arch
Otorhinolaryngol. 271:3233–3239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suh Y, Amelio I, Urbano T Guerrero and
Tavassoli M: Clinical update on cancer: Molecular oncology of head
and neck cancer. Cell Death Dis. 23:e10182014. View Article : Google Scholar
|
|
6
|
Qi W, Huang X and Wang J: Correlation
between Th17 cells and tumour microenvironment. Cell Immunol.
285:18–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Middleton GW, Annels NE and Pandha HS: Are
we ready to start studies of Th17 cell manipulation as a therapy
for cancer? Cancer Immunol Immunother. 61:1–7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ye J, Livergood RS and Peng G: The role
and regulation of human Th17 cells in tumour immunity. Am J Pathol.
182:10–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maddur MS, Miossec P, Kaveri SV and Bayry
J: Th17 cells: Biology, pathogenesis of autoimmune and inflammatory
diseases, and therapeutic strategies. Am J Pathol. 181:8–18. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilke CM, Bishop K, Fox D and Zou W:
Deciphering the role of Th17 cells in human disease. Trends
Immunol. 32:603–611. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kimura A and Kishimoto T: Th17 cells in
inflammation. Int Immunopharmacol. 11:319–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paleri V, Mehanna H and Wight RG: TNM
classification of malignant tumours 7th edition: What's new for
head and neck? Clin Otolaryngol. 35:270–272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Torhorst J, Bucher C, Kononen J, Haas P,
Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, et
al: Tissue microarrays for rapid linking of molecular changes to
clinical endpoints. Am J Pathol. 159:2249–2256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vosse BA, Seelentag W, Bachmann A, Bosman
FT and Yan P: Background staining of visualization systems in
immunohistochemistry: Comparison of the Avidin-Biotin Complex
system and the EnVision+ system. Appl Immunohistochem Mol Morphol.
15:103–107. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyahara Y, Odunsi K, Chen W, Peng G,
Matsuzaki J and Wang RF: Generation and regulation of human CD4+
IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA.
105:pp. 15505–15510. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Llosa NJ, Geis AL, Orberg E Thiele and
Housseau F: Interleukin-17 and type 17 helper T cells in cancer
management and research. Immunotargets Ther. 3:39–54.
2014.PubMed/NCBI
|
|
17
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu J and Paul WE: Heterogeneity and
plasticity of T helper cells. Cell Res. 20:4–12. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu J and Paul WE: CD4 T cells: Fates,
functions, and faults. Blood. 112:1557–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson SD, De Costa AM and Young MR:
Effect of the premalignant and tumour microenvironment on immune
cell cytokine production in head and neck cancer. Cancers (Basel).
6:756–770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Görögh T and Beier UH: Gene alterations in
head and neck carcinomas and their role in promoting malignant
behavior (Review). Int J Oncol. 36:525–532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Douglas WG, Tracy E, Tan D, Yu J, Hicks WL
Jr, Rigual NR, Loree TR, Wang Y and Baumann H: Development of head
and neck squamous cell carcinoma is associated with altered
cytokine responsiveness. Mol Cancer Res. 2:585–593. 2004.PubMed/NCBI
|
|
23
|
Chung Y, Chang SH, Martinez GJ, Yang XO,
Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q and Dong
C: Critical regulation of early Th17 cell differentiation by
interleukin-1 signaling. Immunity. 30:576–587. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park H, Li Z, Yang XO, Chang SH, Nurieva
R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma
L, Xue X, Wei G, Liu X and Fang G: The prevalence of Th17 cells in
patients with gastric cancer. Biochem Biophys Res Commun.
374:533–537. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Acosta-Rodriguez EV, Rivino L, Geginat J,
Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F and Napolitani
G: Surface phenotype and antigenic specificity of human interleukin
17-producing T helper memory cells. Nat Immunol. 8:639–646. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Annunziato F, Cosmi L, Liotta F, Maggi E
and Romagnani S: The phenotype of human Th17 cells and their
precursors, the cytokines that mediate their differentiation and
the role of Th17 cells in inflammation. Int Immunol. 20:1361–1368.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Romagnani S, Maggi E, Liotta F, Cosmi L
and Annunziato F: Properties and origin of human Th17 cells. Mol
Immunol. 47:3–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wägsäter D, Löfgren S, Hugander A and
Dimberg J: Expression of interleukin-17 in human colorectal cancer.
Anticancer Res. 26:4213–4216. 2006.PubMed/NCBI
|
|
30
|
Sfanos KS, Bruno TC, Maris CH, Xu L,
Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB and Drake CG:
Phenotypic analysis of prostate-infiltrating lymphocytes reveals
TH17 and Treg skewing. Clin Cancer Res. 14:3254–3261. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma
L, Xue X, Wei G, Liu X and Fang G: The prevalence of Th17 cells in
patients with gastric cancer. Biochem Biophys Res Commun.
374:533–537. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koyama K, Kagamu H, Miura S, Hiura T,
Miyabayashi T, Itoh R, Kuriyama H, Tanaka H, Tanaka J, Yoshizawa H,
et al: Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and
CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer
reflects disease stage. Clin Cancer Res. 14:6770–6779. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kryczek I, Banerjee M, Cheng P, Vatan L,
Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et
al: Phenotype, distribution, generation, and functional and
clinical relevance of Th17 cells in the human tumour environments.
Blood. 114:1141–1149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gaur P, Qadir GA, Upadhyay S, Singh AK,
Shukla NK and Das SN: Skewed immunological balance between Th17
(CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in
human oral squamous cell carcinoma. Cell Oncol (Dordr). 35:335–343.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kesselring R, Thiel A, Pries R, Trenkle T
and Wollenberg B: Human Th17 cells can be induced through head and
neck cancer and have a functional impact on HNSCC development. Br J
Cancer. 103:1245–1254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bose A, Chakraborty T, Chakraborty K, Pal
S and Baral R: Dysregulation in immune functions is reflected in
tumour cell cytotoxicity by peripheral blood mononuclear cells from
head and neck squamous cell carcinoma patients. Cancer Immun.
8:102008.PubMed/NCBI
|
|
37
|
Chizzolini C, Chicheportiche R, Alvarez M,
De Rham C, Roux-Lombard P, Ferrari-Lacraz S and Dayer JM:
Prostaglandin E2 synergistically with interleukin-23 favors human
Th17 expansion. Blood. 112:3696–3703. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Napolitani G, Acosta-Rodriguez EV,
Lanzavecchia A and Sallusto F: Prostaglandin E2 enhances Th17
responses via modulation of IL-17 and IFN-gamma production by
memory CD4+ T cells. Eur J Immunol. 39:1301–1312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Benchetrit F, Ciree A, Vives V, Warnier G,
Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH and
Tartour E: Interleukin-17 inhibits tumour cell growth by means of a
T-cell-dependent mechanism. Blood. 99:2114–2121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Numasaki M, Watanabe M, Suzuki T,
Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze
MT, Kolls JK and Sasaki H: IL-17 enhances the net angiogenic
activity and in vivo growth of human non-small cell lung cancer in
SCID mice through promoting CXCR-2-dependent angiogenesis. J
Immunol. 175:6177–6189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nam JS, Terabe M, Kang MJ, Chae H, Voong
N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, et al:
Transforming growth factor beta subverts the immune system into
directly promoting tumour growth through interleukin-17. Cancer
Res. 68:3915–3923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kryczek I, Wei S, Szeliga W, Vatan L and
Zou W: Endogenous IL-17 contributes to reduced tumour growth and
metastasis. Blood. 114:357–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ciree A, Michel L, Camilleri-Bröet S,
Louis F Jean, Oster M, Flageul B, Senet P, Fossiez F, Fridman WH,
Bachelez H and Tartour E: Expression and activity of IL-17 in
cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Int J Cancer. 112:113–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Muranski P, Boni A, Antony PA, Cassard L,
Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K,
et al: Tumour-specific Th17-polarized cells eradicate large
established melanoma. Blood. 112:362–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Garcia-Hernandez Mde L, Hamada H, Reome
JB, Misra SK, Tighe MP and Dutton RW: Adoptive transfer of
tumour-specific Tc17 effector T cells controls the growth of B16
melanoma in mice. J Immunol. 184:4215–4227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Honorati MC, Neri S, Cattini L and
Facchini A: IL-17 enhances the susceptibility of U-2 OS
osteosarcoma cells to NK cell lysis. Clin Exp Immunol. 133:344–349.
2003. View Article : Google Scholar : PubMed/NCBI
|
